Patents Examined by Doug Schultz
-
Patent number: 9861668Abstract: This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided.Type: GrantFiled: December 15, 2016Date of Patent: January 9, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: Kah-Whye Peng, Stephen James Russell, Camilo Ayala Breton
-
Patent number: 9845480Abstract: The present invention includes methods for effecting phenotype conversion in a cell by transfecting the cell with phenotype-converting nucleic acid. Expression of the nucleic acids results in a phenotype conversion in the transfected cell. Preferably the phenotype-converting nucleic acid is a transcriptome, and more preferably an mRNA transcriptome.Type: GrantFiled: October 12, 2015Date of Patent: December 19, 2017Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: James Eberwine, Jai-Yoon Sul, Tae Kyung Kim, Vickas Patel
-
Patent number: 9809813Abstract: A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it. This method is based on quantifying T-cell diversity by calculating the number of diverse T-cell receptor (TCR) beta chain variable regions from blood cells.Type: GrantFiled: March 4, 2016Date of Patent: November 7, 2017Assignee: Fred Hutchinson Cancer Research CenterInventors: Harlan S. Robins, Edus H. Warren, III, Christopher Scott Carlson
-
Patent number: 9795643Abstract: The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.Type: GrantFiled: May 22, 2015Date of Patent: October 24, 2017Inventors: Ulrich M. Lauer, Michael Bitzer, Johanna Lampe, Martina Schell, Susanne Berchtold, Sebastian Lange, Wolfgang J. Neubert, Sascha Bossow
-
Patent number: 9790470Abstract: This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (DE) medium comprising a TGFp ligand, fibroblast growth factor (FGF), bone morphogenetic protein (BMP), a PI3K inhibitor and optionally a GSK3 ? inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; FGF; retinoic acid; and a BMP inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising FGF, retinoic acid, a BMP inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising FGF. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells. These methods may be useful, for example, in producing pancreatic cells for therapy or disease modelling.Type: GrantFiled: September 16, 2013Date of Patent: October 17, 2017Assignee: Cambridge Enterprise LimitedInventors: Ludovic Vallier, Hsin-hua Cho
-
Patent number: 9750693Abstract: The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide.Type: GrantFiled: September 29, 2014Date of Patent: September 5, 2017Assignees: Rhode Island Council on Postsecondary Education (Statutory Successor to Rhode Island Board of Governors for Higher Education), Yale UniversityInventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
-
Patent number: 9750826Abstract: Provided is a method for producing a glioblastoma mouse model and the mouse model produced thereby, the method including the steps of: (a) dividing a glioblastoma tissue, isolated from a patient, into 4 or more sections, and collecting one or more pieces from each of the sections; (b) dissociating a mixture of the collected pieces into glioblastoma cells as single cells; and (c) orthotopically transplanting a graft sample containing the glioblastoma cells obtained in step (b), into the brain of an immunodeficient mouse. Further provided are a method of screening a glioblastoma therapeutic agent using the mouse model and a method of providing information for selection of a patient-specific glioblastoma therapy using the mouse model. The glioblastoma mouse model shows the same genetic, morphological and pathological characteristics as those of the parental tumor, and it allows screening patient-specific glioblastoma therapeutic agent or selecting safer and more effective patient-specific glioblastoma therapy.Type: GrantFiled: June 21, 2013Date of Patent: September 5, 2017Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Do Hyun Nam, Ju Yuon Jin, Kyeung Min Joo
-
Patent number: 9743646Abstract: The present invention provides an immuno-deficient animal useful as an animal model for a human disease associated with a first mutation of a target gene, wherein the animal comprises (a) a first human xenograft comprising the target gene comprising the first mutation; (b) a second human xenograft comprising the target gene but lacking the first mutation, wherein the first human xenograft and second human xenograft are isogenic. Also provided here are methods of producing the animal model and methods of using such animal model.Type: GrantFiled: April 6, 2015Date of Patent: August 29, 2017Assignee: CROWN BIOSCIENCE INC. (TAICANG)Inventors: Qian Shi, Yanmei Sun
-
Patent number: 9717749Abstract: The invention relates in aspects to hybrid RNAs lacking a poly-A tail and nucleic acid vectors for expressing the RNA. The hybrid RNAs in some instances have a 3? terminal stabilizing triple helical structure. Related methods for expressing said RNAs in vivo and in vitro are also disclosed.Type: GrantFiled: October 16, 2013Date of Patent: August 1, 2017Assignee: Massachusetts Institute of TechnologyInventors: Jeremy E. Wilusz, Phillip A. Sharp
-
Patent number: 9707303Abstract: The present invention discloses a gene delivery system containing a reduction-sensitive shielding system having a targeting function, a preparation method and an application in the field of gene therapy thereof. The gene delivery system is composed of a reduction-sensitive shielding system having a targeting function, cationic polymer material and plasmid DNA; the cationic polymer material and the plasmid DNA complexed to form complex particles, the reduction-sensitive shielding system having a targeting function is shielded on the complex surface by means of electrostatic interaction, so as to reduce the toxicity of the delivery system and successfully transfer the loaded genetic material into cells, thereby achieving expression of genetic material and completing the transfection process, and moreover, improving the targeting and the efficiency of gene transfection.Type: GrantFiled: September 29, 2013Date of Patent: July 18, 2017Assignee: SICHUAN UNIVERSITYInventors: Zhongwei Gu, Yu Nie, Yiyan He, Gang Cheng, Li Xie
-
Patent number: 9707299Abstract: The invention provides a method for delivering a cargo molecule into a cell using a targeted DNA-based carrier (e.g., DNA dendrimer). Compositions and kits useful in the practice of the methods are also provided.Type: GrantFiled: May 22, 2008Date of Patent: July 18, 2017Assignee: The Trustees of the University of PennsylvaniaInventors: Silvia Muro-Galindo, Vladimir R. Muzykantov
-
Patent number: 9694036Abstract: Methods are provided for efficient production of midbrain dopaminergic (DA) neurons. In some aspects, methods involve differentiation and selection of DA neurons for a transgenic pluripotent cell population (e.g., cells comprising a selectable marker gene). Cell populations produced by the instant methods and methods of their use are likewise provided.Type: GrantFiled: March 20, 2015Date of Patent: July 4, 2017Assignee: Cellular Dynamics International, Inc.Inventors: Matt George, Carrie Chavez, Chris McMahon, Wen Bo Wang, Lucas Chase, Brad Swanson
-
Patent number: 9677086Abstract: Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3?-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.Type: GrantFiled: July 1, 2016Date of Patent: June 13, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David Frendewey, Guochun Gong, Ka-Man Venus Lai, David M. Valenzuela
-
Patent number: 9649379Abstract: The present invention provides pharmaceutical compositions for the treatment of hepatocellular carcinoma (HCC) comprising Notch3 inhibitors and a chemotherapeutic agent, methods for the preparation of said compositions and a medical treatment comprising the administration of said pharmaceutical compositions in patients in need thereof.Type: GrantFiled: July 25, 2007Date of Patent: May 16, 2017Assignee: ALMA MATER STUDIORUM—UNIVERSITA' DI BOLOGNAInventors: Luigi Bolondi, Catia Giovannini, Pásquale Chieco, Kenneth Marcu
-
Patent number: 9637739Abstract: Isolation or in vitro assembly of the Cas9-crRNA complex of the Streptococcus thermophilus CRISPR3/Cas system and use for cleavage of DNA bearing a nucleotide sequence complementary to the crRNA and a proto-spacer adjacent motif. Methods for site-specific modification of a target DNA molecule using an RNA-guided DNA endonuclease comprising at least one RNA sequence and at least one of an RuvC active site motif and an HNH active site motif; for conversion of Cas9 polypeptide into a nickase cleaving one strand of double-stranded DNA by inactivating one of the active sites (RuvC or HNH) in the polypeptide by at least one point mutation; for assembly of active polypeptide-polyribonucleotides complex in vivo or in vitro; and for re-programming a Cas9-crRNA complex specificity in vitro or using a cassette containing a single repeat-spacer-repeat unit.Type: GrantFiled: March 15, 2013Date of Patent: May 2, 2017Assignee: VILNIUS UNIVERSITYInventors: Virginijus {hacek over (S)}ik{hacek over (s)}nys, Giedrius Gasiunas, Tautvydas Karvelis
-
Patent number: 9617514Abstract: In certain embodiments methods are provided for inducing and/or restoring and/or maintaining a non-senescent phenotype, or aspects thereof (e.g., proliferative capacity and/or pluripotency) in a mammalian cell. The methods typically involve reducing the level or activity of SINE/Alu retrotransposon transcripts in the cell in an amount sufficient to induce or restore proliferative capacity and/or pluripotency to said mammalian cell.Type: GrantFiled: October 20, 2011Date of Patent: April 11, 2017Assignee: BUCK INSTITUTE FOR RESEARCH ON AGINGInventor: Victoria V. Lunyak
-
Patent number: 9603877Abstract: The present invention relates to an isolated nucleic acid molecule comprising (a) a first nucleotide sequence encoding a protein that detects the presence, amount or both of a pathogenic microorganism by forming a complex with a quorum sensing molecule produced by said pathogenic microorganism, (b) one or more second nucleotide sequence said one or more second nucleotide sequence being under control of a promoter that is induced by the complex of the protein encoded by the first nucleotide sequence and the quorum sensing molecule produced by said pathogenic microorganism and encoding (i) an antimicrobial peptide, wherein the antimicrobial peptide is effective against the pathogenic microorganism detected by the protein encoded by the first nucleotide sequence; and/or an antibiofilm enzyme wherein the antibiofilm enzyme is effective against the pathogenic microorganism detected by the protein encoded by the first nucleotide sequence; and (c) optionally a third nucleotide sequence encoding a protein that controType: GrantFiled: March 11, 2015Date of Patent: March 28, 2017Assignee: NANYANG TECHNOLOGICAL UNIVERSITYInventors: Matthew Wook Chang, In Young Hwang, Mui Hua Tan, Elvin Koh
-
Patent number: 9596834Abstract: Fatty liver was induced by administering agents for inducing organ inflammation to experimental animals to evoke insulin resistance and by rearing them with high-fat diets. As a result, steatohepatitis was successfully induced in the animals. The animals show pathological findings similar to those of humans. By using these model animals, substances for treating or preventing diseases can be efficiently screened and the efficacy of medicinal substances can be effectively evaluated.Type: GrantFiled: February 27, 2014Date of Patent: March 21, 2017Assignee: Stelic Institute of Regenerative Medicine, Stelic Institute & Co.Inventors: Hiroyuki Yoneyama, Masato Fujii
-
Patent number: 9598672Abstract: Provided is a matrix for promoting survival and differentiation of cells transplanted thereon, comprising a base matrix and a cell-made matrix thereon. Methods and means for making and using same are also provided. Also provided are conditioned media, related compositions, related methods, and related packaging products.Type: GrantFiled: December 24, 2014Date of Patent: March 21, 2017Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Ilene Sugino, Marco Zarbin, Qian Sun, Raymond B. Birge
-
Patent number: 9588107Abstract: The present invention relates to the field of endothelial haematopoietic transition (EHT) and epithelial-mesenchymal transition (EMT) and more particularly relates to the use of fish embryo or larva as a model for the study of EHT and EMT.Type: GrantFiled: July 14, 2010Date of Patent: March 7, 2017Assignee: AZELEADInventors: Karima Kissa-Marin, Philippe Herbomel